For UK pharmaceutical and life sciences leaders
The UK regulatory environment is making your R&D budget harder to justify every year
A combination of NICE cost-effectiveness thresholds, slow market access, and post-Brexit complexity has driven a sustained decline in UK pharma R&D investment, and the trajectory is not improving.
Two minutes. Solva follows up with specific market access and investment strategy options.
- Major pharmaceutical companies announcing reduced R&D budgets for their UK operations
- A decrease in the number of new drug approvals or clinical trials initiated in the UK
- Scientists and researchers relocating from the UK to other countries with more favourable R&D environments
- A noticeable decline in the UK's share of global pharmaceutical investment reports
- Reduced capacity for drug discovery and development within the UK
- Increased reliance on imported pharmaceutical innovations
- Loss of high-value R&D jobs and economic contribution
- Reduced tax revenues from pharmaceutical companies
- Delayed access to innovative treatments for UK patients
- Reduced participation in cutting-edge clinical trials
- Erosion of the UK's standing as a global leader in life sciences
- Decreased attractiveness for international research collaborations
- The decline in UK pharmaceutical R&D investment is primarily driven by a combination of factors: the stringent and often unpredictable NICE cost-effectiveness hurdles, which make market access for new drugs challenging; the complexities and uncertainties introduced by post-Brexit regulatory divergence from the EU; and a less competitive fiscal and incentive environment compared to other global R&D hubs.
- These structural issues create an unattractive landscape for global pharmaceutical companies seeking to allocate their R&D budgets.
Pharmaceutical industry investment in R&D fell by nearly £100 million in 2023 (ABPI, 2025)
How to fix it
A UK R&D investment strategy covering the regulatory pathway, market access landscape, and the commercial case for UK investment produces a clear recommendation for the global leadership team within three to four weeks.
Frequently asked questions
Why does this problem persist?
The UK lost £1.3 billion in R&D investment in 2023. The combination of NICE cost-effectiveness hurdles, slow market access, and post-Brexit regulatory complexity is making the UK a less attractive R&D location for global pharma companies.
What is the cost of leaving it unaddressed?
The UK could lose out on £11 billion in pharmaceuticals research and development (R&D) investment by 2033 (WPI Economics, 2025)
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.